Article Text

Download PDFPDF
EV447/#460  Hematological malignancies in ovarian cancer survivors-salvaged by bone marrow transplant
  1. Amita Naithani1,
  2. Angad Sekhon2 and
  3. Rahul Naithani3
  1. 1Artemis Hospital, Divison of Gynaecologic Oncolgy, Surgical Oncology, Gurugram, India
  2. 2Max Hospital, Clinical Research, Saket, India
  3. 3Paras Health, Hematology and Bone Marrow Transplant, Gurugram, India

Abstract

Introduction Improving outcomes of patients with ovarian malignancies has led to emergence of second malignacies in survivors. We report two patients who developed hematological malignancies and were further salvaged by bone marrow transplant.

Methods Retrospective study

Results A 39-year-old female underwent cytoreductive surgery for granulosa cell tumor in 2016. She was kept on observation. Two years later, she presented with pain in right hip joint. PET CT demonstrated a soft tissue mass 3 cm × 2 cm in right retro-orbital region (SUV 15.2), a large lytic lesion with thinning of cortex in right femur , and multiple FDG avid lytic bone lesions. She was diagnosed with multiple myeloma R-ISS Stage I. She was treated with carfilzomib, lenalidomide and dexamethasone based therapy followed by autologous bone marrow transplant in June 2019. She continues to be myeloma and ovarian malignancy free at her last follow-up in April 2024. A 51-year-old female was diagnosed with epithelial cancer ovary in 2018. She underwent cytoreductive surgery in Dec 2018 followed by adjuvant chemotherapy till April 2019. She presented with fever and low blood counts in Oct 2020. She was diagnosed with secondary acute myeloid leukemia. She received 3+7 chemotherapy, achieved remission and underwent a haploidentical bone marrow transplant from her son in Dec 2020. Transplant course was complicated by pulmonary aspergillosis and CMV reactivation. She continues to be leukemia free and ovarian malignancy free at her last follow-up in March 2024.

Conclusion/Implications Survivors of ovarian malignancy developing secondary hematological malignancy can continue to hope for good outcomes.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.